EP2157964A1 - Utilisation cosmétique d'un dérivé d'acide imidopercaboxylique comme agent desquamant - Google Patents

Utilisation cosmétique d'un dérivé d'acide imidopercaboxylique comme agent desquamant

Info

Publication number
EP2157964A1
EP2157964A1 EP08776467A EP08776467A EP2157964A1 EP 2157964 A1 EP2157964 A1 EP 2157964A1 EP 08776467 A EP08776467 A EP 08776467A EP 08776467 A EP08776467 A EP 08776467A EP 2157964 A1 EP2157964 A1 EP 2157964A1
Authority
EP
European Patent Office
Prior art keywords
group
skin
composition
acid
acid derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP08776467A
Other languages
German (de)
English (en)
Inventor
Pascale Pelletier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LOreal SA
Original Assignee
LOreal SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LOreal SA filed Critical LOreal SA
Publication of EP2157964A1 publication Critical patent/EP2157964A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4913—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid
    • A61K8/492—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid having condensed rings, e.g. indol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
    • A61K2800/28—Rubbing or scrubbing compositions; Peeling or abrasive compositions; Containing exfoliants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/007—Preparations for dry skin

Definitions

  • the present invention relates to the cosmetic use of at least one imidopercarboxylic acid derivative in a cosmetic composition comprising a physiologically acceptable medium, as agent for promoting desquamation of the skin and/or the scalp and/or for stimulating epidermal renewal.
  • skin is understood to mean, in a broad sense, the skin and the semimucous membranes (lips).
  • Desquamation is a natural phenomenon linked to the fact that the epidermis, which constitutes the top layer of the skin and of the scalp, is constantly regenerated.
  • the epidermis consists of several strata of cells, of which the deepest is the basal stratum consisting of undifferentiated cells. Over the course of time, these cells will differentiate and migrate to the surface of the epidermis, thereby constituting the various strata of the latter, as far as forming, at the surface of the epidermis, the corneocytes which are dead cells which are removed by desquamation. This surface loss is compensated by the migration of cells of the basal stratum to the surface of the epidermis. This constitutes the perpetual renewal of the skin. A forced elimination of the horny layer accelerates the renewal and makes it possible to combat ageing.
  • these cells continue their differentiation, the last stage of which is the corneocyte. It in fact consists of dead cells which constitute the last layer of the epidermis, that is to say the outermost layer also called stratum corneum.
  • the desquamation process may be adversely affected by exogenous factors (for example: UV radiation, pollution, allergenic agents, pathogens), and/or endogenous factors (for example: hormonal changes, age%) and may lead in particular to a slowing of epidermal renewal and consequently ageing of the skin, and/or thickening of the horny layer (for example: formation of callosities), and/or desquamative disorders of the aesthetic type (for example: dandruff, squamae%) or of the pathological type (for example: xerosis, ichthyosis, psoriasis, atopic dermatitis).
  • exogenous factors for example: UV radiation, pollution, allergenic agents, pathogens
  • endogenous factors for example: hormonal changes, age
  • endogenous factors for example: hormonal changes, age
  • desquamative disorders of the aesthetic type for example: dandruff, squamae
  • the pathological type for example: xerosis,
  • Some of these signs of ageing are more particularly linked to intrinsic or physiological ageing, that is to say to age-related "normal” or chronobio logical ageing, while others are more specific to extrinsic ageing, that is to say ageing caused in a general manner by the environment; it is more particularly photoageing due to exposure to the sun, to light or to any other radiation.
  • the skin changes due to intrinsic ageing are the consequence of a genetically programmed senescence in which endogenous factors are involved.
  • This intrinsic ageing causes in particular slowing of the renewal of skin cells, which results mainly in the appearance of clinical impairments such as the reduction in the subcutaneous adipose tissue and the appearance of fine wrinkles or fine lines, and in histopathological changes such as an increase in the number and the thickness of elastic fibres, a loss in vertical fibres of the membrane of the elastic tissue, and the presence of large irregular fibroblasts in the cells of this elastic tissue.
  • extrinsic ageing causes clinical impairments such as thick wrinkles and the formation of a soft and weather-beaten skin, and histopathological changes such as an excessive accumulation of elastic material in the top dermis and degeneration of the collagen fibres.
  • the invention relates in particular to intrinsic or physiological ageing as well as extrinsic ageing.
  • agents intended for combating skin ageing are known in the prior art, among which are antioxidants, agents promoting proliferation and/or differentiation of dermal and/or epidermal cells, agents stimulating the expression of dermal or epidermal macromolecules, that is as many agents as cellular or molecular targets in the skin for preventing and/or reducing the multiple effects of skin ageing.
  • patent US-A-4603146 describes the use of retinoic acid and its derivatives in cosmetic compositions for combating skin ageing.
  • these agents intended for combating skin ageing are also desquamating agents.
  • desquamating agents act by facilitating the elimination of the dead cells located at the surface of the horny layer of the epidermis. This "desquamating" property is also called, often wrongly, keratolytic properties.
  • ⁇ -hydroxy acids such as lactic acid or glycolic acid
  • BHA ⁇ -hydroxy acids
  • the problem which the present invention aims to solve moreover consists in providing novel methods which make it possible to maintain or improve the appearance of the skin.
  • the inventors have discovered, surprisingly, that some imidopercarboxylic acid derivatives possess a desquamating action on the skin and/or on the scalp.
  • a method is moreover known from the document US 6 309 654 for improving microcirculation in the skin, comprising the topical application of a pharmaceutical composition containing an activated oxygen-containing compound, including a peroxycarboxylic acid.
  • a pharmaceutical composition containing an activated oxygen-containing compound including a peroxycarboxylic acid.
  • Some peroxycarboxylic acids are also known, for example from the document WO 96/05802, to be capable of being used in oral compositions for whitening the teeth.
  • compositions including cosmetic compositions, for example in cream form, comprising phthalimidopercarboxylic acid in the form of an adduct with cyclodextrin.
  • the invention relates to the cosmetic use of at least one imidopercarboxylic derivative in a cosmetic composition comprising a physiologically acceptable medium, as cosmetic agent intended for promoting desquamation of the skin and/or the scalp and/or for stimulating epidermal renewal.
  • the composition is intended for preventing, attenuating and/or combating the signs of skin ageing.
  • the composition is intended for improving the appearance and/or the texture of the skin and/or of the scalp.
  • the said composition may also be intended for improving the radiance and the homogeneity of the complexion and/or for smoothing the skin.
  • the said composition is intended for reducing the surface irregularities and the skin microrelief.
  • the said composition is intended for promoting the elimination of dead cells at the surface of the body.
  • the composition is intended for improving the staying power of the make-up.
  • the subject of the invention is a cosmetic and/or dermatological composition
  • a cosmetic and/or dermatological composition comprising, in a physiologically acceptable medium, at least one imidopercarboxylic derivative and at least one auxiliary desquamating agent in particular chosen from beta-hydroxy acids such as salicylic acid and its derivatives, in particular 5-n-octanoylsalicylic acid, urea and its derivatives chosen from hydroxyethylurea, in particular N-(2-hydroxyethyl)urea marketed under the name Hydrovance ® by National Starch, a thiourea, N-2-hydroxyethylpiperazine-N-2- ethanesulphonic acid (HEPES), Sophora japonica extract, honey, N-acetylglucosamine, 2-oxothiazolidine-4-carboxylic acid (procysteine) derivatives, extracts of laminaira such as laminaria saccharina and laminaria ochroleuca and mixtures
  • the subject of the invention is a cosmetic and/or dermatological composition
  • a cosmetic and/or dermatological composition comprising, in a physiologically acceptable medium, at least one imidopercarboxylic derivative and at least one anti-ageing agent in particular chosen from an antiglycation agent, an NO-synthase inhibitor, an agent acting on dermal or epidermal macromolecules and/or preventing their degradation, an agent modulating the differentiation or the proliferation of cells, and in particular the differentiation of the keratinocytes and/or the proliferation of the fibroblasts or of the keratinocytes and a muscle relaxant and/or a skin relaxant.
  • the subject of the invention is also a method of cosmetic treatment in particular for non-therapeutic care of the skin and/or the scalp, intended for promoting desquamation of the skin and/or of the scalp and/or for stimulating epidermal renewal, characterized in that it comprises the application, to the skin and/or the scalp, of a composition comprising at least one imidoperoxycarboxylic acid derivative, in particular a compound of formula (I) or (II) as defined below.
  • the invention also relates to a peeling method.
  • the invention relates to a method for the cosmetic treatment of the visible and/or tactile irregularities of the human skin, comprising the steps consisting in: a) topically applying to the skin a composition comprising at least one imidopercarboxylic acid derivative, b) leaving the composition in contact with the skin for an appropriate period for the pro-desquamating action of the said derivative, which may be between 5 min and 6 hours, preferably between 5 min and 30 min, and c) eliminating the composition by rinsing.
  • the method in accordance with the invention is additionally most particularly intended for at least one of the conditions chosen from: preventing, attenuating and/or combating the signs of skin ageing, and in particular attenuating wrinkles and fine lines, improving the appearance and/or the texture of the skin, in particular improving the homogeneity of the complexion and/or smoothing the skin, and in particular attenuating acne or chickenpox marks and/or clearing the skin pores.
  • composition for carrying out the method of cosmetic treatment for the non-therapeutic care of the skin and/or of the scalp or the cosmetic use according to the invention is more particularly intended for promoting desquamation of the skin and/or of the scalp, and/or for stimulating epidermal renewal, and in particular for treating at least one of the conditions chosen from:
  • DHA dihydroxyacetone
  • the invention relates to a method of cosmetic treatment, in particular for the non-therapeutic care, of the skin, intended for preventing, attenuating and/or combating the signs of skin ageing, characterized in that it comprises the application, to the skin, of a composition comprising at least one imidoperoxycarboxylic acid derivative, in particular a compound of formula (I) or (II) as defined below.
  • the invention relates to a method of cosmetic treatment, in particular for the non-therapeutic care, of the skin and/or of the scalp, in particular of aged skin and/or of dry skin, intended for improving the appearance and/or the structure of the skin and/or of the scalp, characterized in that it comprises the application, to the said skin and/or the said scalp, of a composition comprising at least one imidoperoxycarboxylic acid derivative, in particular a compound of formula (I) or (II) as defined below.
  • the invention relates to a method of cosmetic treatment, in particular for the non-therapeutic care of the skin, in particular of aged skin and/or of dry skin, intended for improving the radiance and the homogeneity of the complexion and/or for smoothing the skin, characterized in that it comprises the application, to the said skin, of a composition comprising at least one imidoperoxycarboxylic acid derivative, in particular a compound of formula (I) or (II) as defined below.
  • the invention relates to a method of cosmetic treatment, in particular for the non-therapeutic care of the skin, in particular of aged skin and/or of dry skin, intended for reducing the surface irregularities and the skin microrelief, characterized in that it comprises the application, to the said skin, of a composition comprising at least one imidoperoxycarboxylic acid derivative, in particular a compound of formula (I) or (II) as defined below.
  • the invention relates to a method of cosmetic treatment, in particular for the non-therapeutic care of the skin and/or of the scalp, in particular of aged skin and/or of dry skin, intended for promoting the elimination of dead cells at the surface of the body, characterized in that it comprises the application, to the said skin and/or the said scalp, of a composition comprising at least one imidoperoxycarboxylic acid derivative, in particular a compound of formula (I) or (II) as defined below.
  • the invention relates to a method of cosmetic treatment, in particular for the non-therapeutic care of the scalp, intended for promoting the elimination of dandruff, characterized in that it comprises the application, to the scalp, of a composition comprising at least one imidoperoxycarboxylic acid derivative, in particular a compound of formula (I) or (II) as defined below.
  • the invention relates to a method of cosmetic treatment, in particular for the non-therapeutic care of the skin, intended for improving the staying power of the make-up and/or for improving the result of treatment with colorants for the stratum corneum such as dihydroxyacetone (DHA), characterized in that it comprises the application, to the skin, of a composition comprising at least one imidoperoxycarboxylic acid derivative, in particular a compound of formula (I) or (II) as defined below.
  • DHA dihydroxyacetone
  • the improvement in the staying power of the make-up and/or in the treatments for colouring the skin with DHA results from the fact that the skin and/or the scalp may be prepared before the abovementioned making up and/or colouring by applying a composition according to the invention, which will promote the result of a simultaneous or subsequent treatment with a make-up agent or a colouring agent.
  • signal of skin ageing is understood to mean any modification of the external appearance of the skin and/or its texture due to chronological or photoinduced ageing such as, for example, wrinkles, fine lines, withered skin, flabby skin, skin of reduced thickness, lack of skin elasticity or tone.
  • the prodesquamating activity is indeed mainly desired in the field of so-called anti-ageing compositions, namely compositions intended for combating the skin signs due to ageing and/or photoageing.
  • the combination used according to the present invention may also find applications in the attenuation of the surface irregularities of the skin and the improvement of the skin microrelief, in particular the attenuation of acne or chickenpox marks, the clearing of the skin pores and the treatment of dry skin.
  • the aromatic imidopercarboxylic acid derivative may be applied to any region of the skin or of its annexes, in particular of the face, of the neck and shoulders, of the hands, or on the lips, in order to attenuate the visible and/or tactile irregularities of the skin, for example in order to attenuate scars, in order to smooth the surface and/or eliminate the dead skins in particular of the lips.
  • the imidopercarboxylic acid derivative makes it possible to promote desquamation of the skin and/or to stimulate epidermal renewal and therefore more particularly to treat skin and/or scalp pathologies linked to a production of a thickened horny layer and/or linked to an abnormal desquamation.
  • the present invention also relates, according to another of its aspects, to the use of at least one imidopercarboxylic acid derivative for the preparation of a dermatological composition intended for treating skin and/or scalp pathologies which are characterized by the production of a thickened horny layer and/or by an abnormal desquamation.
  • a dermatological composition intended for treating skin and/or scalp pathologies which are characterized by the production of a thickened horny layer and/or by an abnormal desquamation.
  • these skin and/or scalp disorders linked to deregulation of desquamation there may be mentioned, in the context of the present invention: xerosis, hyperkeratosis, psoriasis, atopic dermatitis, and ichthyosis.
  • the imidopercarboxylic acid derivative according to the invention makes it possible to promote desquamation of the skin and/or of the scalp and/or to stimulate epidermal renewal and may therefore be used for the preparation of a dermatological composition intended for treating the abovementioned skin pathologies which are characterized by the production of a thickened horny layer and/or by abnormal desquamation.
  • the imidopercarboxylic acid derivative according to the invention makes it possible to treat the callosities or hyperkeratosis of dry feet.
  • imidopercarboxylic acid derivative finds another application in the field of chemical peelings.
  • Peelings are a well-known means for improving the appearance and/or the texture of the skin and/or the scalp, in particular for improving the radiance and the homogeneity of the complexion and/or for reducing the visible and/or tactile irregularities of the skin, and in particular for improving the surface appearance of the skin, for attenuating acne or chickenpox marks, and for preventing, attenuating or combating the signs of skin ageing, and in particular for smoothing the irregularities of the skin texture, such as wrinkles and fine lines.
  • the invention therefore relates to a peeling composition
  • a peeling composition comprising, in a physiologically acceptable medium, at least one aromatic imidopercarboxylic acid derivative and in particular a compound of formula (I) or (II), as defined below and in accordance with the present invention, in an amount greater than 10% by weight of active material relative to the total weight of the composition, in particular ranging from 11% to 60% by weight of active material, in particular from 11 to 40% and more preferably still from 11 to 30% by weight of active material, relative to the total weight of the composition.
  • the subject of the invention is also a method for the treatment, in particular the cosmetic treatment, of the visible and/or tactile irregularities of the human skin, comprising the steps consisting in: a) topically applying to the skin a composition comprising at least one imidopercarboxylic acid derivative, b) leaving the composition in contact with the skin for an appropriate period for the pro-desquamating action of the said derivative, which may be between 5 min and 6 hours, preferably between 5 min and 30 min, and c) eliminating the composition by rinsing.
  • the invention relates to a method, in particular a cosmetic method, for promoting desquamation of the skin and/or of the mucous membranes, comprising at least one step (i) for preparing the skin for peeling consisting in applying to the regions to be treated at least one imidopercarboxylic acid derivative, at least at a suitable concentration for causing desquamation, and (ii) a subsequent step comprising the application of at least one other auxiliary desquamating agent at a concentration less than that causing the desquamation.
  • a step of eliminating the desquamating agent(s) by rinsing will then be performed.
  • step (i) may be repeated with increasing concentrations of imidopercarboxylic acid derivative.
  • concentrations will be adjusted by persons skilled in the art according to the desired effect and the number of applications envisaged, but will be generally less than 50%. It will be possible, for example, to use a first concentration of about 10%, and then one or more successive applications with a concentration of about 5%, and then 5 or 3% by weight of active material relative to the total weight of the composition.
  • This method is more particularly intended for preventing, attenuating and/or combating the signs of skin ageing, and in particular attenuating wrinkles and fine lines, and improving the appearance and/or the texture of the skin, in particular improving the homogeneity of the complexion and/or smoothing the skin, and in particular attenuating acne or chickenpox marks, and/or clearing skin pores.
  • the imidopercarboxylic acid derivative is represented by the compound of formula (I) which follows,
  • Ri and R 2 represent independently of each other (i) a hydrogen atom, (ii) a (Ci-C5)alkyl group optionally substituted with one or more, preferably with one to three groups chosen from a (Ci-Cs)alkoxy group, -OH group, the -COOH group, the -COOOH group, a -COOR 4 group, the -NO 2 group and a halogen atom or (iii) a (Ci-Cs)alkoxy group, or else Ri and R 2 form together
  • A represents a benzene or naphthalene ring optionally substituted with one or more, preferably up to 4, and more preferably still with 1 or 2 groups chosen from a radical R3, a (Ci-C 5 )alkoxy group, the -OH group, the -COOH group, the -COOOH group, a -COOR 4 group, the -NO 2 group and a halogen atom, the R group(s), which are identical or different, represent(s) a hydrogen atom, an -OH group, a -COOH group, a -COOOH group, a -COOR 4 group or a radical R 3 ,
  • R3 represents a (Ci-Cs)alkyl group optionally substituted with one or more, preferably with one to three groups chosen from a (Ci-Cs)alkoxy group, the -OH group, the -COOH group, the -COOOH group, a -COOR 4 group, the -NO 2 group and a halogen atom,
  • R 4 represents a (Ci-C 5 )alkyl group optionally substituted with a group chosen from a (Ci-Cs)alkoxy group, the -OH group, the -COOH group, the -COOOH group, and a -COOR5 group where R5 is a (Ci-C5)alkyl group, and n is an integer varying from 1 to 11, in particular from 1 to 5, and for example from 1 to 3 or for example from 3 to 5.
  • the compound of formula (I) or (II) comprises all the optional enantiomers and mixtures thereof and the corresponding salts or any dimer of the compound of formula (I) or (II).
  • the salts there may be mentioned the potassium salts or the ammonium salts for example.
  • Examples of (Ci-Cs)alkyl groups are methyl, ethyl, n- and i-propyl, n-, i-, sec- and tert-butyl and pentyl.
  • the (Ci-Cs)alkoxy groups there may be mentioned methoxy and ethoxy.
  • the halogen atoms there may be mentioned fluorine, chlorine and bromine.
  • substituted (Ci-Cs)alkyl groups there may be mentioned in particular the groups -CH 2 OCH 3 , -CH 2 OC 2 H 5 , -CH 2 OH, -CH 2 COOH, -CH 2 COOOH, -CH 2 CH 2 COOH, -CH 2 CH 2 COOOH, -CH 2 Cl, -CH 2 F, -CF 3 and -CH 2 COOC 2 H 5 .
  • the R group is a hydrogen atom.
  • A represents a benzene ring.
  • A is substituted with at least one -COOH group or one -COOOH group.
  • the subject of the invention is more particularly the cosmetic use of at least one aromatic imidopercarboxylic acid derivative of formula (II) for which A is an unsubstituted benzene or naphthalene ring, R is a hydrogen atom, a -COOOH group or a (Ci-C 3 )alkyl group optionally substituted with a -COOOH group or a -COOH group, and n varies from 3 to 5, in a composition comprising a physiologically acceptable medium, as agent intended for promoting desquamation of the skin and/or of the scalp and/or for stimulating epidermal renewal.
  • formula (II) for which A is an unsubstituted benzene or naphthalene ring, R is a hydrogen atom, a -COOOH group or a (Ci-C 3 )alkyl group optionally substituted with a -COOOH group or a -COOH group, and n varies from 3 to
  • the compound of formula (II) is phthalimidoperoxycaproic acid, also called 6-(phthalamidoperoxy)hexanoic acid, e- (phthalimidoperoxy)hexanoic acid or PAP. Its chemical structure is as follows:
  • the PAP dimer also called 5,7-dihydro-l,3,5,7-tetraoxobenzo[l,2-c:4,5- c']dipyrrole-2,6(lH,3H)-dihexaneperoxoic acid of formula isD — C ⁇ — £— ⁇ CH ⁇ ; ⁇ C- ⁇ -- * (Ot 2 > J — CH s - C- O ⁇ m
  • the quantity of compound of formula (I) or (II) can be used according to the invention, of course derived from the desired effect, should be an effective quantity for promoting desquamation of the skin and/or of the scalp and/or for stimulating epidermal renewal.
  • the quantity of imidopercarboxylic acid derivative, in particular of compound of formula (I) or (II), that can be used according to the invention may range for example from 0.1 to 50%, in particular from 1 to 50%, in particular from 0.1 to 20%, in particular from 1 to 20%, and preferably from 0.1 to 10%, in particular from 1 to 10% by weight of active material, relative to the total weight of the composition.
  • 0.1 to 10% by weight of active material will be used relative to the total weight of the composition, in particular 0.2 to 5% by weight, and preferably 0.2 to 2% by weight of active material, relative to the total weight of the said composition.
  • an amount greater than 10% by weight of active material will be preferably used relative to the total weight of the composition, in particular ranging from 11% to 50% by weight of active material, in particular from 11 to 40% and more preferably still from 11 to 30% by weight of active material, relative to the total weight of the composition.
  • PAP phthalamidoperoxycaproic or phthalamidoperoxyhexanoic acid
  • phthalamidoperoxycaproic acid may be used together with cyclodextrins so as to improve the stability of the compound.
  • Such an encapsulated product is sold by the company SOLVAY under the trade name EURECO ® HC-P11 (Powdered inclusion complex of Phthalimidoperoxycaproic acid with pharmagrade ⁇ -cyclodextrin).
  • the phthalamidoperoxycaproic acid is also supplied in the form of an aqueous dispersion (containing 17% of active material) under the trade name EURECO ® HC L17.
  • the phthalamidoperoxycaproic acid is also supplied in the form of an aqueous dispersion (containing 5% of active material) under the trade name EURECO ® HC L5.
  • the phthalamidoperoxycaproic acid is also supplied in the form of a powder under the trade name EURECO ® HC-Pl 1 (containing 11% of active material).
  • Such aqueous dispersions of phthalamidoperoxycaproic acid are described in the document EP 1 074 607. These aqueous dispersions are in reality stabilized by copolymers of methyl vinyl ether with maleic acid and/or anhydride, in a 1 :1 ratio, having an alternating structure.
  • phthalamidoperoxycaproic acid non- complexed with cyclodextrin will be used in powdered form or in the form of an aqueous dispersion.
  • a preferred form is an aqueous dispersion.
  • galenic forms comprising an imidopercarboxylic acid derivative may also be suitable for carrying out the present invention.
  • dispersions in particular aqueous dispersions, as described in patent application WO 2004/110610, capsules comprising a gel-based matrix as described in patent application WO 2004/110611, capsules based on an inorganic salt as described in application WO 2004/110612 or multilayer capsules comprising at least one polyelectrolyte and/or one ionic surfactant as described in patent application WO 2004/110613.
  • the compound of formula (I) may be used in combination with an auxiliary desquamating agent, in particular chosen from beta- hydroxy acids such as salicylic acid and its derivatives, in particular 5-n-octanoylsalicylic acid, urea and its derivatives chosen from a hydroxyethylurea, in particular N-(2-hydroxyethyl)urea marketed under the name Hydrovance ® by National Starch, a thiourea, N-2-hydroxyethylpiperazine-N-2-ethanesulphonic acid (HEPES), Sophora japonica extract, honey, N-acetylglucosamine, 2-oxothiazolidine-4-carboxylic acid (procysteine) derivatives, extracts of laminaria saccharina and laminaria ochroleuca and mixtures thereof.
  • an auxiliary desquamating agent in particular chosen from beta- hydroxy acids such as salicylic acid and its derivatives, in particular 5-n-octano
  • this object of the present invention is also a care composition for the skin and/or the scalp, comprising the combination of a derivative of formula (I) or (II) and an auxiliary desquamating agent, characterized in that the auxiliary desquamating agent is chosen from beta-hydroxy acids, such as salicylic acid and its derivatives, in particular 5-n-octanoylsalicylic acid; urea and its derivatives chosen from hydroxyethylurea, in particular N-(2-hydroxyethyl)urea marketed under the name Hydrovance ® by National Starch, thiourea; (N-2-hydroxyethylpiperazine-N-2-ethane)sulphonic acid (HEPES); Sophora japonica extract; honey; N-acetylglucosamine, 2-oxothiazolidine-4-carboxylic acid (procysteine) derivatives, extracts of laminaria such as laminaria saccharina and laminaria ochroleuca and mixtures
  • the composition will contain at least salicylic acid and/or one of its derivatives, in particular 5-n-octanoylsalicylic acid.
  • the said composition will contain 5-n-octanoylsalicylic acid.
  • the composition will contain 5-n-octanoylsalicylic acid and salicylic acid.
  • the composition may also contain another desquamating agent, called hereinafter "additional desquamating agent" belonging to the general list of desquamating agents proposed below.
  • additional desquamating agent belonging to the general list of desquamating agents proposed below.
  • saturated and unsaturated monocarboxylic acids saturated and unsaturated dicarboxylic acids, saturated and unsaturated tricarboxylic acids
  • alpha hydroxy acids and beta hydroxy acids of monocarboxylic acids alpha-hydroxy acids and beta-hydroxy acids of dicarboxylic acids
  • alpha-hydroxy acids and beta-hydroxy acids of tricarboxylic acids keto acids, alpha-keto acids, beta-keto acids of polycarboxylic acids, polyhydroxy monocarboxylic acids, polyhydroxy bicarboxylic acids, polyhydroxy tricarboxylic acids
  • (3-hydroxy-2- pentylcyclopentyl)acetic acid such as: saturated and unsaturated monocarboxylic acids, saturated and unsaturated dicarboxylic acids, saturated and unsaturated tricarboxylic acids
  • alpha hydroxy acids and beta hydroxy acids of monocarboxylic acids alpha-hydroxy acids and beta-hydroxy acids of dicarboxylic acids
  • ⁇ -hydroxy acids there may be mentioned: glycolic acid, citric acid, lactic acid, tartric acid, malic acid or mandelic acid.
  • the preferred ⁇ -hydroxy acids are chosen from: salicylic acid and its derivatives, in particular 5-n-octanoylsalicylic acid.
  • desquamating agents there may be mentioned: pyruvic, gluconic, glucuronic, oxalic, malonic, succinic, acetic, gentisic, cinnamic and azelaic acids; phenol, resorcinol; oligofucoses as in patent EP 0 218 200; jasmonic acid and its derivatives as in patent applications EP 1 333 022 and EP 1 333 021; trichloroacetic acid; retinoids such as retinol, retinoic acid; adapalene; resveratrol; and their salts and derivatives, such as their cis or trans forms, the racemic mixtures, the dextrorotatory or levorotatory forms of the abovementioned agents.
  • corneodesmosomes such as glycosidases, stratum corneum chymotryptic enzyme (SCCE) or even other proteases (trypsin, chymotrypsin-like).
  • SCCE stratum corneum chymotryptic enzyme
  • trypsin, chymotrypsin-like enzymes involved in desquamation or the degradation of the corneodesmosomes, such as glycosidases, stratum corneum chymotryptic enzyme (SCCE) or even other proteases (trypsin, chymotrypsin-like).
  • SCCE stratum corneum chymotryptic enzyme
  • glycerol trilactate silicon derivatives of salicylate as in patent EP 0 796 861, salts of 5-acylsalicylic acid, active agents having effects on transglutaminase as in patent EP 0 899 330, and a flower extract of the f ⁇ cus Opuntia indica such as Exfolactive ® from Silab.
  • the auxiliary desquamating agent is chosen from 5-n-octanoylsalicylic acid, (N-2-hydroxyethylpiperazine-N-2-ethane)- sulphonic acid (HEPES), derivatives of 2-oxothiazolidine-4-carboxylic acid (procysteine) and mixtures thereof.
  • 5-n-octanoylsalicylic acid will be used.
  • Persons skilled in the art will know how to define the required quantity of total desquamating agent, namely of auxiliary desquamating agent and additional desquamating agent optionally present in combination in order to obtain the desired effect on the skin and/or the scalp.
  • the auxiliary desquamating agent and the additional desquamating agent may be present in an amount ranging from 0.001 to 95% by weight relative to the total weight of the composition, in particular from 0.01 to 30% by weight relative to the total weight of the composition and preferably from 0.01 to 10% by weight relative to the total weight of the composition.
  • the composition used according to the invention may in particular comprise from 0.01 to 90% by weight of desquamating agent(s) in their entirety relative to the total weight of the composition, preferably from 1 to 70% by weight relative to the total weight of the composition.
  • the peeling compositions there will be used in the peeling compositions at least 10% by weight, and in particular more than 20% by weight, in particular from 21 to 50%, and preferably from 21 to 30% of auxiliary desquamating agent and additional desquamating agent relative to the total weight of the composition.
  • composition which can be used according to the present invention may additionally comprise at least one cosmetic and/or dermatological additional agent intended for improving the appearance and/or the comfort of the skin and/or of the scalp.
  • This additional agent may be in particular an anti-ageing and/or anti-wrinkle agent in particular chosen from an antiglycation agent, an NO-synthase inhibitor, an agent acting on the dermal or epidermal macromolecules and/or preventing their degradation, an agent modulating the differentiation or the proliferation of the cells, and in particular the differentiation of the keratinocytes and/or the proliferation of the fibroblasts or of the keratinocytes, a muscle relaxant and/or skin relaxant.
  • an anti-ageing and/or anti-wrinkle agent in particular chosen from an antiglycation agent, an NO-synthase inhibitor, an agent acting on the dermal or epidermal macromolecules and/or preventing their degradation, an agent modulating the differentiation or the proliferation of the cells, and in particular the differentiation of the keratinocytes and/or the proliferation of the fibroblasts or of the keratinocytes, a muscle relaxant and/or skin relaxant.
  • the additional agent may also be a moisturizing agent, a soothing agent or a mixture.
  • the anti-ageing and/or anti-wrinkle agent may in particular be chosen from: an antiglycation agent, such as an extract of bilberry (Vaccinium myrtillus), for example that sold under the name "BLUEBERRY HERBASOL EXTRACT PG" by the company COSMETOCHEM, a black tea extract such as Kombuchka from Sederma, or lipoic or thioctic acid such as Nutralip ® from Labochim; an NO-synthase inhibitor, such as extracts of Gingko biloba, of Vitis vinifera or of Olea europaea; an agent acting on dermal or epidermal macromolecules and/or preventing their degradation, such as Centella asiatica extracts, asiaticosides and derivatives; ascorbic acid and its derivatives; synthetic peptides such as iamine, biopeptide CL or palmitoyl pentapeptide marketed by the company SEDERMA under the trade name Matrixyl
  • additional anti-ageing agents are generally present in the cosmetic compositions which can be used according to the present invention in amounts ranging from 0.01 to 20% by weight relative to the total weight of the composition, preferably from 0.01 to 10% by weight relative to the total weight of the composition and more preferably still from 0.01 to 1% by weight relative to the total weight of the composition.
  • the invention also relates to a cosmetic and/or dermatological composition
  • a cosmetic and/or dermatological composition comprising: at least one imidopercarboxylic acid derivative, in particular a compound of formula (I) or (II), and at least one auxiliary desquamating agent as detailed above for example chosen from 5-n-octanoylsalicylic acid, (N-2-hydroxyethylpiperazine-N-2-ethane)- sulphonic acid (HEPES), and mixtures thereof.
  • auxiliary desquamating agent as detailed above for example chosen from 5-n-octanoylsalicylic acid, (N-2-hydroxyethylpiperazine-N-2-ethane)- sulphonic acid (HEPES), and mixtures thereof.
  • the invention also relates to a cosmetic and/or dermatological composition
  • a cosmetic and/or dermatological composition comprising: at least one imidopercarboxylic acid derivative, in particular a compound of formula (I) or (II), and at least one additional anti-ageing agent, and preferably at least two anti- ageing agents chosen from adenosine, a malt extract, a Padina pavonica extract, a Centella asiatica extract, a soybean extract, a wild yam extract, an agent modulating the differentiation or the proliferation of cells, and in particular the differentiation of the keratinocytes and/or proliferation of the fibroblasts or of the keratinocytes, as defined above and mixtures thereof and optionally a moisturizing agent and/or a soothing agent.
  • moisturizing agents for the treatment of dry skin, it will be advantageous to use, as additional agent in the composition of the invention, moisturizing agents, soothing agents and mixtures thereof.
  • moisturizing agents there may be mentioned in particular hyaluronic acid, homopolymers of acrylic acid such as Lipidure-HM ® from NOF Corporation, beta-glucan and in particular sodium carboxymethyl-beta-glucan from Mibelle-AG-Biochemistry; a mixture of passionflower, apricot, corn and rice bran oils marketed by Nestle under the name NutraLipids ® ; a C-glycoside derivative such as those described in application WO 02/051828 and in particular C- ⁇ -D-xylopyranoside-2-hydroxypropane in the form of a solution containing 30% by weight of active material in a water/propylene glycol mixture (60/40% by weight) such as the product manufactured by CHIMEX under the trade name "MEXORYL SBB ® "; a musk rose oil marketed by Nestle; a zinc-enriched extract of the microalga prophyridium cruentrum marketed by Vincience under the name Algualane Zinc®
  • ⁇ -glycyrrhetinic acid and its salts or derivatives stearyl glycyrrhetate, 3-stearoyloxyglycyrrhetic acid, glycyrrhetinic acid monoglucuronide
  • plants containing them for example: Glycyrrhiza glabra
  • ursolic acid and its salts Centella asiatica extracts, Canola oil, bisabolol; camomile extracts, allantoin; a mixture of water lily flower extract and palmitoylproline such as that sold under the name "Seppicalm VG ® " by the company Seppic; Aloe vera, rose water, an extract of mint, in particular of mint leaves such as Calmiskin ® from Silab, filamentous bacteria such as Vitreoscilla f
  • the invention also relates to a cosmetic and/or dermatological composition
  • a cosmetic and/or dermatological composition comprising: at least one imidopercarboxylic acid derivative, in particular a compound of formula (I) or (II), and at least one additional agent chosen from a moisturizing agent, a soothing agent and mixtures thereof, and preferably at least two agents chosen from hyaluronic acid, a mixture of passionflower, apricot, corn and rice bran oils marketed by Nestle under the name NutraLipids ® ; a C-glycoside derivative such as those described in application WO 02/051828 and in particular C- ⁇ -D-xylopyranoside-2-hydroxypropane in the form of a solution containing 30% by weight of active material in a water/propylene glycol mixture (60/40% by weight) such as the product manufactured by CHIMEX under the trade name "MEXORYL SBB ® "; a musk rose oil marketed by Nestle; spheres of
  • compositions which can be used according to the invention comprise a physiologically acceptable medium.
  • physiologically acceptable medium is understood to mean a medium compatible with the keratin fibres and/or materials of human beings, such as for example, without limitation, the skin, the mucous membranes, the nails, the scalp and/or the hair.
  • This physiologically acceptable medium comprises water, optionally mixed or not mixed with one or more organic solvents such as Ci-Cs alcohols, in particular ethanol, isopropanol, tert-butanol, n-butanol, polyols such as glycerine, propylene glycol, butylene glycol and polyol ethers.
  • organic solvents such as Ci-Cs alcohols, in particular ethanol, isopropanol, tert-butanol, n-butanol, polyols such as glycerine, propylene glycol, butylene glycol and polyol ethers.
  • compositions which can be used according to the invention may be a cosmetic or dermatological composition and may therefore comprise a cosmetically or pharmaceutically acceptable medium.
  • the composition may also comprise a fatty phase, which may comprise oils, gums, waxes customarily used in the field of application considered.
  • oils or waxes which can be used in the invention, there may be mentioned mineral oils (liquid paraffin), vegetable oils (liquid fraction of shea butter, sunflower oil, apricot oil, rice bran oil and the like), animal oils (perhydrosqualene) synthetic oils (purcellin oil), silicone oils or waxes (cyclomethicone, dimethicone) and fluorinated oils (perfluoropolyethers), beeswax, carnauba wax or paraffin wax, shea butter, hydrogenated jojoba oil.
  • Fatty alcohols cetyl alcohol, stearyl alcohol and the like
  • fatty acids stearic acid and the like
  • the proportion of the fatty phase may range from 5% to 80% by weight, and preferably from 5% to 50% by weight relative to the total weight of the composition.
  • the oils, waxes, emulsifiers and coemulsifiers used in the composition in the form of an emulsion are chosen from those conventionally used in the cosmetic field.
  • the emulsifier and the coemulsifier are present in the composition in a proportion ranging from 0.3% to 30% by weight, and preferably from 0.5 to 20% by weight relative to the total weight of the composition.
  • the emulsion may additionally contain lipid vesicles.
  • the fatty phase may represent more than 90% of the total weight of the composition.
  • the composition may also contain the usual adjuvants in the field considered, such as surfactants, emulsifiers, hydrophilic or lipophilic gelling agents, hydrophilic or lipophilic additives, preservatives, antioxidants, solvents, perfumes, fillers, screening agents, odour absorbers and colouring matter, other cosmetic or pharmaceutical active agents.
  • the quantities of these various adjuvants are those conventionally used in the cosmetic field, and are for example from 0.01% to 10% of the total weight of the composition.
  • These adjuvants depending on their nature, may be introduced into the fatty phase, into the aqueous phase and/or into the lipid spherules.
  • hydrophilic gelling agents which can be used in the invention, there may be mentioned carboxyvinyl polymers (carbomer), acrylic copolymers such as acrylate/alkyl acrylate copolymers, polyacrylamides, polysaccharides such as hydroxypropylcellulose, natural gums and clays, and, as lipophilic gelling agents, there may be mentioned modified clays such as bentones, metal salts of fatty acids such as aluminium stearates and hydrophobic silica, ethyl cellulose, polyethylene.
  • the composition may be provided in all the conceivable galenic forms.
  • the composition may be in the form of an aqueous, alcoholic, aqueous-alcoholic or oily solution; a dispersion of the lotion or serum type; a water-in-oil, oil-in-water or multiple emulsion; a suspension; microcapsules or microparticles; vesicular dispersions of the ionic and/or non- ionic type; an aqueous or oily lotion or in serum form; a foam, a solid preparation, for example a stick; an aerosol composition also comprising a propellant under pressure or in the form of a patch.
  • composition which can be used according to the invention may be provided in the form of a composition for hair care, in particular a shampoo, a hair setting lotion, a treatment lotion, a hair styling cream or gel, a dye composition, in particular an oxidation dye, composition, restructuring lotions for the hair, a permanent-waving composition (in particular a composition for the first stage of a permanent waving), an anti-hair-loss lotion or gel, an antiparasitic shampoo.
  • a composition for hair care in particular a shampoo, a hair setting lotion, a treatment lotion, a hair styling cream or gel, a dye composition, in particular an oxidation dye, composition, restructuring lotions for the hair, a permanent-waving composition (in particular a composition for the first stage of a permanent waving), an anti-hair-loss lotion or gel, an antiparasitic shampoo.
  • a cleansing, protective, treatment or care composition for the face, for the hands, for the feet, for the large anatomical folds or for the body (for example day creams, night cream, makeup-removing cream, anti-sun composition, protection or care body milks, after-sun milks, care lotion, gel or foam for the skin, such as cleansing lotion, artificial tanning composition); a make-up composition for the body or the face such as a foundation; a bath composition; a deodorant composition comprising for example a bactericidal agent; an aftershave composition; a depilatory composition; a composition for insect bites; an anti-pain composition; a composition for treating certain skin diseases such as eczema, rosacea, psoriasis, lichens and severe pruritus.
  • a cleansing, protective, treatment or care composition for the face, for the hands, for the feet, for the large anatomical folds or for the body (for example day creams, night cream, makeup-removing cream, anti-s
  • the composition which can be used according to the invention may also be provided in all the galenic forms mentioned above as long as it can be easily removed by rinsing, and in particular in the form of an aqueous gel, an aqueous or aqueous-alcoholic solution. It may be applied by any means allowing uniform distribution and in particular with the aid of cotton wool, a wand, a brush, a gauze, a spatula or a pad, or else by spraying, and may be removed by rinsing with water or with the aid of a mild detergent. According to a preferred embodiment of the invention, the composition intended for chemical peeling contains a continuous aqueous phase.
  • PAP phthalimidoperoxycaproic acid
  • AG reference glycolic acid
  • Example 4 Composition for dry skin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cosmetics (AREA)

Abstract

La présente invention concerne l'utilisation cosmétique d'au moins un dérivé d'acide imidopercarboxylique dans une composition cosmétique comprenant un milieu physiologiquement acceptable, comme agent permettant de favoriser la desquamation de la peau et/ou du cuir chevelu et/ou permettant de stimuler le renouvellement épidermique. L'invention concerne également le procédé associé de traitement cosmétique et une composition comprenant ledit dérivé d'acide imidopercarboxylique et un agent desquamant et/ou un agent anti-vieillissement.
EP08776467A 2007-06-26 2008-06-24 Utilisation cosmétique d'un dérivé d'acide imidopercaboxylique comme agent desquamant Withdrawn EP2157964A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0756026A FR2917969B1 (fr) 2007-06-26 2007-06-26 Utilisation cosmetique d'un derive d'acide imido-percarboxylique a titre d'agent desquamant
US98155207P 2007-10-22 2007-10-22
PCT/IB2008/052507 WO2009001296A1 (fr) 2007-06-26 2008-06-24 Utilisation cosmétique d'un dérivé d'acide imidopercaboxylique comme agent desquamant

Publications (1)

Publication Number Publication Date
EP2157964A1 true EP2157964A1 (fr) 2010-03-03

Family

ID=39066547

Family Applications (1)

Application Number Title Priority Date Filing Date
EP08776467A Withdrawn EP2157964A1 (fr) 2007-06-26 2008-06-24 Utilisation cosmétique d'un dérivé d'acide imidopercaboxylique comme agent desquamant

Country Status (4)

Country Link
US (1) US20100189675A1 (fr)
EP (1) EP2157964A1 (fr)
FR (1) FR2917969B1 (fr)
WO (1) WO2009001296A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006037922A1 (fr) * 2004-10-04 2006-04-13 L'oreal Composition cosmetique et/ou dermatologique pour peaux sensibles
FR2889057B1 (fr) * 2005-08-01 2008-07-18 Oreal Composition cosmetique et/ou dermatologique pour la prevention et/ou le traitement des peaux sensibles ou seches
FR2920304B1 (fr) * 2007-09-04 2010-06-25 Oreal Utilisation cosmetique de lysat bifidobacterium species pour le traitement de la secheresse.
FR2920305B1 (fr) * 2007-09-04 2010-07-30 Oreal Utilisation d'un lysat de bifidobacterium species pour le traitement de peaux sensibles.
FR2953407B1 (fr) * 2009-12-08 2013-06-14 Oreal Microorganismes probiotiques a titre d'actif contre les alterations du microrelief
FR2957522B1 (fr) 2010-03-17 2012-04-20 Oreal Utilisation cosmetique d'un derive d'acide imido-peroxycarboxylique pour diminuer la taille des pores de la peau
FR2957521B1 (fr) 2010-03-17 2012-03-02 Oreal Composition cosmetique comprenant un derive d'acide imido-peroxycarboxylique et un copolymere d'acide 2-acrylamido-2-methylpropane-sulfonique
WO2012076345A1 (fr) 2010-12-06 2012-06-14 L'oreal Composition cosmétique comprenant un acide imidoperoxycarboxylique, un acide imidocarboxylique et un copolymère d'acide 2-acrylamido-2-méthyl- propanesulfonique
FR2968958B1 (fr) 2010-12-17 2015-06-26 Oreal Composition cosmetique comprenant un derive acide imido-peroxycarboxylique et un compose bis-akyl sulfosuccinate
FR2973232B1 (fr) * 2011-03-31 2014-08-15 Oreal Association d'acide salicylique et d'un derive d'acide imido-peroxycarboxylique en tant qu'agent apaisant
US9717757B1 (en) * 2011-12-28 2017-08-01 Samuel N. Gasque, Jr. Composition and method to treat and prevent muscle cramping
FR2999914B1 (fr) * 2012-12-21 2015-08-07 Oreal Utilisation de derives de l'acide imidocarboxylique pour traiter les alterations de la peau liees a l'age ou au photovieillissement
EP3875099A4 (fr) * 2018-10-30 2022-07-27 Murata Manufacturing Co., Ltd. Régulateur d'expression génique de protéine de choc thermique, médicament, produit cosmétique et procédé de production de régulateur d'expression génique de protéine de choc thermique
US12064504B2 (en) 2021-10-31 2024-08-20 L'oreal Cosmetic compositions comprising high amounts of trifluoromethylhenyl valylglycine
US12090224B2 (en) 2021-10-31 2024-09-17 L'oreal Cosmetic composition comprising high amounts of ceramide-np

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4603146A (en) * 1984-05-16 1986-07-29 Kligman Albert M Methods for retarding the effects of aging of the skin
GB2210789A (en) * 1987-10-10 1989-06-21 Morrison Dr Ian Donald Topical application for skin care
FR2732594B1 (fr) * 1995-04-07 1997-06-06 Oreal Utilisation de derives d'acide salicylique pour la depigmentation de la peau
GB9626778D0 (en) * 1996-12-23 1997-02-12 Procter & Gamble Hair coloring compositions
IT1293820B1 (it) * 1997-08-05 1999-03-10 Ausimont Spa Composizioni a base di perossiacidi
DE19818914C2 (de) * 1998-04-23 2000-03-02 Gabriele Wyeth Ohg Kosmetik Be Verwendung von peroxidierten organischen Verbindungen mit "aktiviertem Sauerstoff" zur Verbesserung der Mikrozirkulation des Blutes in der Haut
US20030147977A1 (en) * 2000-05-03 2003-08-07 Goodman David S. Topical preparation for treating acne and hirsutism
CA2338124C (fr) * 2001-02-26 2010-08-03 Valerie Dumont Dicianna Composition autobronzante sous forme de substrat en feuilles
DE102005054565A1 (de) * 2005-11-14 2007-05-16 Henkel Kgaa Oxidationsmittel enthaltende,wohlriechende Verbrauchsprodukte
FR2899467B1 (fr) * 2006-04-07 2008-05-30 Oreal Utilisation de derive c-glycosides comme agent protecteur et/ou activateur des lymphocytes gamma delta t
US20080008673A1 (en) * 2006-07-03 2008-01-10 Claudie Willemin Compositions comprising at least one C-glycoside derivative

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2009001296A1 *

Also Published As

Publication number Publication date
US20100189675A1 (en) 2010-07-29
FR2917969A1 (fr) 2009-01-02
WO2009001296A1 (fr) 2008-12-31
FR2917969B1 (fr) 2010-12-10

Similar Documents

Publication Publication Date Title
US20100189675A1 (en) Cosmetic use of an imidopercarboxylic acid derivative as desquamating agent
JP3843943B2 (ja) Ｎ−アシルアミノ−アミドファミリーの新規な化合物、それを含有する組成物及び用途
EP1021161B1 (fr) Utilisation de l'acide ellagique et de ses derives en cosmetique et en dermatologie
JP4072433B2 (ja) ２−オキソチアゾリジン−４−カルボン酸誘導体の剥離促進剤としての使用
EP1932564A1 (fr) Utilisation cosmétique de l'acide anisique pour favoriser la desquamation
JP2006131633A (ja) 皮膚の老化の徴候を抑制する尿素化合物の使用
JP4117774B2 (ja) Ｎ−アシルアミノアミドファミリーのエラスターゼ阻害剤化合物と少なくとも１種の抗炎症剤化合物の組み合わせを含む化粧品用又は皮膚用組成物
JP2006232858A (ja) 皮膚の剥離を促進するための組成物における少なくとも１つのアミノスルホン酸誘導体の使用
US9421157B2 (en) Use of C-glycoside derivatives as pro-desquamating active agents
FR2755367A1 (fr) Utilisation d'un extrait de potentille erecta dans le domaine de la cosmetique et de la pharmacie, notamment de la dermatologie
JP5329830B2 (ja) Ｓｃｆ分泌抑制剤、及び皮脂分泌抑制剤
KR20050103903A (ko) 노화되거나 환경에 손상된 피부를 치료하기 위한 국소적조성물 및 치료 방법
EP1442736A1 (fr) Utilisation de l'acide 3-0-acétyl 11-céto-boswellique ou d'un extrait végétal en contenant, pour réduire les rides d'expression
FR2903009A1 (fr) Composition cosmetique et/ou dermatologique associant un derive de c-glycoside et un agent desquamant
KR20170088420A (ko) N-아실아미노-아미드 부류의 신규한 화합물, 이를 포함하는 조성물, 및 용도
FR3005408A1 (fr) Utilisation d'acide petroselinique pour lutter contre les desordres esthetiques de la silhouette lies aux modifications du tissu adipeux
KR20180108255A (ko) 파리신 비를 포함하는 화장료 조성물
KR20090105222A (ko) 모공 축소용 화장료 조성물
JP2008094799A (ja) 硫酸化グリコサミノグリカン産生促進剤およびこれを含有する皮膚外用剤
KR20180108254A (ko) 파리신 a를 포함하는 화장료 조성물
WO2008004164A2 (fr) Composition cosmétique et/ou dermatologique combinant un dérivé de c-glycoside et un agent desquamant
KR20240064514A (ko) 바쿠치올을 포함하는, 피부 개선용 화장료 조성물
KR20100036644A (ko) 코릴라진을 유효성분으로 함유하는 화장료 조성물
CN118234480A (zh) 局部组合物和其用途
FR2821554A1 (fr) Compositions topiques contenant au moins un derive d'ethanolamine pour le traitement ou la prevention des dommages de la peau associes au vieillissement de la peau et procedes comestique associes

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20091203

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA MK RS

17Q First examination report despatched

Effective date: 20100526

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20140103